Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay.

导出 OA

翻译打印收藏纠错

作者： Carlos,Rodríguez-Antolín ^[1] ; Rocío,Rosas-Alonso ^[2] ; Patricia,Cruz ^[1] ; Oliver,Higuera ^[2] ; Darío,Sánchez-Cabrero ^[3] ; Isabel,Esteban-Rodríguez ^[2] ; Alberto,Peláez-García ^[3] ; Victoria Eugenia,Fernández Montaño ^[2] ; Carmen,Rodríguez-Jiménez ^[3] ; Inmaculada,Ibáñez de Cáceres ^[2] ; Javier,de Castro ^[3]

作者单位： Epigenetics Laboratory, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain. ^[1] Experimental Therapies and Novel Biomarkers in Cancer, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. ^[2] Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain. ^[3] Department of Pathology, Hospital Universitario La Paz, Madrid, Spain. ^[4] Molecular Pathology and Therapeutic Targets, Hospital Universitario La Paz Institute for Health Research (IdiPAZ), Madrid, Spain. ^[5] Structural and Functional Genomics, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain. ^[6] Genetics of Metabolic Diseases, Department of Genetics, Hospital Universitario La Paz, Madrid, Spain. ^[7]

关键词 Crizotinib Fusion gene Lung cancer Molecular diagnosis Next-generation sequencing ROS1